Alejandro Balsa , Petra Díaz del Campo Fontecha , Lucía Silva Fernández , José Valencia Martín , Virginia Nistal Martínez , Fernando León Vázquez , M. Vanesa Hernández Hernández , Héctor Corominas , Rafael Cáliz Cáliz , José María Aguado García , Gloria Candelas Rodríguez , Nora Ibargoyen Roteta , Arturo Martí Carvajal , M. Nieves Plana Farras , Janet Puñal Riobóo , Hye Sang Park , Yolanda Triñanes Pego , Virginia Villaverde García
{"title":"西班牙风湿病学会关于类风湿关节炎患者生物治疗和JAK抑制剂风险管理的建议","authors":"Alejandro Balsa , Petra Díaz del Campo Fontecha , Lucía Silva Fernández , José Valencia Martín , Virginia Nistal Martínez , Fernando León Vázquez , M. Vanesa Hernández Hernández , Héctor Corominas , Rafael Cáliz Cáliz , José María Aguado García , Gloria Candelas Rodríguez , Nora Ibargoyen Roteta , Arturo Martí Carvajal , M. Nieves Plana Farras , Janet Puñal Riobóo , Hye Sang Park , Yolanda Triñanes Pego , Virginia Villaverde García","doi":"10.1016/j.reumae.2023.07.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p><span><span>To present recommendations based on the available evidence and the consensus of experts, for risk management of biological treatment and </span>JAK inhibitors </span>in patients<span> with rheumatoid arthritis.</span></p></div><div><h3>Methods</h3><p><span>Clinical research questions relevant to the purpose of the document were identified. These questions were reformulated in PICO format (patient, intervention, comparison, outcome or outcome) by a panel of experts, selected based on their experience in the area. A </span>systematic review of the evidence was carried out, grading according to the GRADE criteria (Grading of Recommendations Assessment, Development, and Evaluation). Specific recommendations were then formulated.</p></div><div><h3>Results</h3><p><span>6 PICO questions were proposed by the panel of experts based on their clinical relevance and the existence of recent information regarding the risk of occurrence of serious infections, the risk of reactivation of the hepatitis B virus, the risk of reactivation of the virus varicella-zoster, the risk of appearance of skin (melanoma and non-melanoma) or </span>haematological cancer<span><span>, the risk of appearance of thromboembolic disease and the risk of progression of the </span>human papilloma virus.</span></p><p>A total of 28 recommendations were formulated, structured by question, based on the evidence found and the consensus of the experts.</p></div><div><h3>Conclusions</h3><p>The SER recommendations on risk management of treatment with biologic therapies and JAK inhibitors in rheumatoid arthritis are presented.</p></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis\",\"authors\":\"Alejandro Balsa , Petra Díaz del Campo Fontecha , Lucía Silva Fernández , José Valencia Martín , Virginia Nistal Martínez , Fernando León Vázquez , M. Vanesa Hernández Hernández , Héctor Corominas , Rafael Cáliz Cáliz , José María Aguado García , Gloria Candelas Rodríguez , Nora Ibargoyen Roteta , Arturo Martí Carvajal , M. Nieves Plana Farras , Janet Puñal Riobóo , Hye Sang Park , Yolanda Triñanes Pego , Virginia Villaverde García\",\"doi\":\"10.1016/j.reumae.2023.07.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p><span><span>To present recommendations based on the available evidence and the consensus of experts, for risk management of biological treatment and </span>JAK inhibitors </span>in patients<span> with rheumatoid arthritis.</span></p></div><div><h3>Methods</h3><p><span>Clinical research questions relevant to the purpose of the document were identified. These questions were reformulated in PICO format (patient, intervention, comparison, outcome or outcome) by a panel of experts, selected based on their experience in the area. A </span>systematic review of the evidence was carried out, grading according to the GRADE criteria (Grading of Recommendations Assessment, Development, and Evaluation). Specific recommendations were then formulated.</p></div><div><h3>Results</h3><p><span>6 PICO questions were proposed by the panel of experts based on their clinical relevance and the existence of recent information regarding the risk of occurrence of serious infections, the risk of reactivation of the hepatitis B virus, the risk of reactivation of the virus varicella-zoster, the risk of appearance of skin (melanoma and non-melanoma) or </span>haematological cancer<span><span>, the risk of appearance of thromboembolic disease and the risk of progression of the </span>human papilloma virus.</span></p><p>A total of 28 recommendations were formulated, structured by question, based on the evidence found and the consensus of the experts.</p></div><div><h3>Conclusions</h3><p>The SER recommendations on risk management of treatment with biologic therapies and JAK inhibitors in rheumatoid arthritis are presented.</p></div>\",\"PeriodicalId\":94193,\"journal\":{\"name\":\"Reumatologia clinica\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reumatologia clinica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2173574323001569\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia clinica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173574323001569","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis
Objective
To present recommendations based on the available evidence and the consensus of experts, for risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis.
Methods
Clinical research questions relevant to the purpose of the document were identified. These questions were reformulated in PICO format (patient, intervention, comparison, outcome or outcome) by a panel of experts, selected based on their experience in the area. A systematic review of the evidence was carried out, grading according to the GRADE criteria (Grading of Recommendations Assessment, Development, and Evaluation). Specific recommendations were then formulated.
Results
6 PICO questions were proposed by the panel of experts based on their clinical relevance and the existence of recent information regarding the risk of occurrence of serious infections, the risk of reactivation of the hepatitis B virus, the risk of reactivation of the virus varicella-zoster, the risk of appearance of skin (melanoma and non-melanoma) or haematological cancer, the risk of appearance of thromboembolic disease and the risk of progression of the human papilloma virus.
A total of 28 recommendations were formulated, structured by question, based on the evidence found and the consensus of the experts.
Conclusions
The SER recommendations on risk management of treatment with biologic therapies and JAK inhibitors in rheumatoid arthritis are presented.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
